Galapagos’ BioFocus DPI service division has signed two collaborations with Ono Pharmaceutical Company. "The new contracts show the benefit of building a global drug discovery service business," says Onno van de Stolpe, CEO of Galapagos. “We combine expertise from our acquired companies Discovery Partners International, BioFocus, as well as Inpharmatica, realizing the synergy in bringing these activities together.”
Under the first collaboration, BioFocus DPI will use selected compounds from its SoftFocus and other synthetic small molecule collections to perform high-throughput screening for Ono's drug discovery program.
In the second deal, BioFocus DPI will apply its medicinal and computational chemistry and ADME profiling expertise in multiple medicinal chemistry projects for Ono.